• 1. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 2. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431

Comprehensive Guide to N-Boc-D-cyclohexylglycinol (CAS No. 188348-00-7): Properties, Applications, and Industry Insights

N-Boc-D-cyclohexylglycinol (CAS No. 188348-00-7) is a high-value chiral building block widely used in pharmaceutical synthesis, agrochemical research, and advanced material science. This Boc-protected amino alcohol derivative has gained significant attention due to its stereochemical purity and versatility in asymmetric synthesis. With the growing demand for enantiomerically pure compounds in drug development, N-Boc-D-cyclohexylglycinol has become a crucial intermediate for designing novel therapeutic agents targeting neurological disorders and metabolic diseases.

The compound's unique structural features combine a cyclohexyl group with a glycinol moiety, protected by a tert-butoxycarbonyl (Boc) group. This configuration provides exceptional stability during synthetic transformations while allowing selective deprotection when needed. Recent studies highlight its role in developing peptide mimetics and small molecule inhibitors, particularly in COVID-19 related research where protease inhibitors have shown therapeutic potential. Researchers frequently search for "N-Boc-D-cyclohexylglycinol solubility" and "N-Boc-D-cyclohexylglycinol synthetic route," reflecting the compound's practical challenges and synthetic importance.

From a commercial perspective, CAS 188348-00-7 has seen steady market growth, with manufacturers focusing on GMP-grade production to meet pharmaceutical industry standards. Analytical data shows increasing searches for "N-Boc-D-cyclohexylglycinol price" and "bulk suppliers," indicating expanding industrial applications. The compound's low toxicity profile and excellent chiral purity (typically >98% ee) make it particularly valuable for API synthesis where regulatory compliance is critical.

Innovative applications continue to emerge, including its use in metal-organic frameworks (MOFs) for catalytic systems and as a precursor for liquid crystal materials. The cyclohexyl ring contributes to enhanced lipophilicity, making derivatives of N-Boc-D-cyclohexylglycinol valuable for improving drug bioavailability. Recent patent literature reveals its incorporation in kinase inhibitors and G-protein coupled receptor (GPCR) modulators, addressing current therapeutic needs in oncology and inflammation.

Quality control parameters for 188348-00-7 typically include rigorous testing for residual solvents, heavy metal content, and enantiomeric excess. Advanced analytical techniques like HPLC-MS and chiral chromatography ensure batch-to-batch consistency. Environmental considerations have also shaped production methods, with manufacturers adopting green chemistry principles to reduce waste generation during Boc protection/deprotection steps.

The future outlook for N-Boc-D-cyclohexylglycinol remains positive, driven by sustained demand in peptide therapeutics and targeted drug delivery systems. As the pharmaceutical industry shifts toward more complex molecules, this compound's role as a versatile chiral synthon will likely expand. Ongoing research explores its potential in bioconjugation chemistry and prodrug development, particularly for CNS-active compounds where the cyclohexyl group enhances blood-brain barrier penetration.

For researchers working with N-Boc-D-cyclohexylglycinol, proper storage conditions (typically 2-8°C under inert atmosphere) and handling procedures are essential to maintain stability. The compound's crystalline form offers advantages in purification and characterization compared to oily analogues. With increasing interest in continuous flow chemistry, adaptations of traditional synthetic routes for CAS 188348-00-7 are being developed to improve efficiency and scalability.

• 106391-87-1(Boc-D-valinol)
• 106930-51-2(Boc-D-Leucinol)
• 79069-14-0(Boc-L-Valinol)
• 82010-31-9(Boc-Leucinol)
• 106946-74-1(Boc-Isoleucinol)
• 107202-39-1((S)-Tert-Butyl (1-cyclohexyl-2-hydroxyethyl)carbamate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)